This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Yeda Research and Develpment & Co. Ltd. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Assaf Marcus: Innovator in Immunotherapy
Introduction
Assaf Marcus is a prominent inventor based in Rehovot, Israel. He has made significant contributions to the field of immunotherapy, particularly in the treatment of diseases such as cancer. His innovative approach focuses on utilizing redirected allogeneic cells to enhance therapeutic outcomes.
Latest Patents
Assaf Marcus holds a patent for a method titled "Immunotherapy using redirected allogeneic cells." This patent describes a technique for treating diseases by administering an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor shortly after partial lymphodepletion. The method also includes administering agents that delay the egression of the allogeneic T cells from lymph nodes during the adoptive transfer process, effectively trapping the T cells in the lymph nodes for improved efficacy.
Career Highlights
Assaf is associated with Yeda Research and Development Co. Ltd., where he continues to advance his research in immunotherapy. His work has garnered attention for its potential to revolutionize cancer treatment through innovative cellular therapies.
Collaborations
Some of his notable coworkers include Zelig Eshhar and Tova Waks, who have collaborated with him on various research projects aimed at enhancing the effectiveness of immunotherapy.
Conclusion
Assaf Marcus is a key figure in the field of immunotherapy, with a focus on innovative methods that leverage allogeneic T cells for cancer treatment. His contributions are paving the way for new therapeutic strategies that could significantly impact patient care.